Ophthalmology specialty – Talk Bio

Actionable Insights Powered by AI

Lilly Expands Gene Therapy Presence with Acquisition of Adverum Biotechnologies

1 day ago talkbio0Tagged Acquisition, Adverum Biotechnologies, contingent value, eli lilly, gene therapy, ixovec, Ophthalmology specialty, Wet Age-Related Macular Degeneration

Eli Lilly; Adverum Biotechnologies; gene therapy; ophthalmology; wet age-related macular degeneration; ixovec; acquisition; contingent value rights

FDA Rejects Sydnexis Myopia Drug for Kids; Chugai to Buy Renalys for $98M Upfront

2 days ago talkbio0Tagged Chugai, Complete Response Letter, methionine, Myopia, Ophthalmology specialty, Pediatric brand name, Renalys, SYD-101, Sydnexis, United States Food and Drug Administration

FDA; SYD-101; Sydnexis; myopia; pediatric; complete response letter; Chugai; Renalys; acquisition; $98M; ophthalmology

Diorasis Therapeutics Welcomes Dr. Dimitri Azar to Its Board of Directors

6 days ago talkbio0Tagged Biotechnology, board of directors, Clinical Development, Dimitri Azar, Diorasis, gene therapy, Glaucoma, Ophthalmology specialty, United States Food and Drug Administration

Diorasis Therapeutics; Dimitri Azar; Board of Directors; gene therapy; glaucoma; ophthalmology; biotechnology; FDA; clinical development

Fierce Biotech Fundraising Tracker ’25: Avenzo adds $60M Series B; Ollin debuts with $100M

1 month ago talkbio0Tagged Antibodies, Bispecific, Avenzo, Clinical Trials, Neoplasms, Ollin Biosciences, Ophthalmology specialty, pipeline development, Series B financing, venture capital

Avenzo Therapeutics; Series B financing; Ollin Biosciences; biotech fundraising; oncology; ophthalmology; venture capital; pipeline development; bispecific antibody; clinical trials

Regeneron and Sandoz Settle Eylea Biosimilar Patent Dispute

2 months ago talkbio0Tagged Approved, Biosimilars, Enzeevu, Eylea, launch, Ophthalmology specialty, Patent Settlement, Regeneron, sandoz, United States, United States Food and Drug Administration

Regeneron; Sandoz; Eylea; Enzeevu; biosimilar; aflibercept; patent settlement; FDA approval; U.S. launch; ophthalmology

Kowa Secures Expanded Rights to Nicox’s Glaucoma Drug NCX 470 in Major Global Deal

3 months ago talkbio0Tagged Clinical Trials, Denali, Glaucoma, Kowa, licensing agreement, milestone payments, naproxen-n-butyl nitrate, Ophthalmology specialty, royalties, TLX2 gene

Kowa; Nicox; NCX 470; glaucoma; exclusive rights; licensing agreement; Denali clinical trial; ophthalmology; royalties; milestone payments

Surrozen sets its sights on ophthalmology after binning liver programme

7 months ago talkbio0Tagged Ophthalmology specialty, Severe (severity modifier)

Ophthalmology specialty, Severe (severity modifier)

Capsida and AbbVie’s Gene Therapy Collaboration Yields Promising Results for Eye Diseases

10 months ago talkbio0Tagged AbbVie, Capsida Biotherapeutics, Dependovirus, gene therapy, genetic medicines, Ophthalmology specialty, strategic collaboration

Capsida Biotherapeutics, AbbVie, gene therapy, eye diseases, strategic collaboration, adeno-associated virus (AAV) engineering platform, ophthalmology, genetic medicines.

Regeneron Expands Ophthalmology Portfolio with Acquisition of UK-Based Biotech Oxular

10 months ago talkbio0Tagged Acquisition, biotech, Drug Delivery Systems, Ophthalmology specialty, Oxular, Regeneron, Retinal Diseases, Technology

Regeneron, Oxular, Biotech Acquisition, Ophthalmology, Retinal Disorders, Drug Delivery Technology

Beacon Therapeutics Raises $170 Million to Advance Ocular Gene Therapy

1 year ago talkbio0Tagged AGTC-501, Beacon, Infrequent, J&J, ocular gene therapy, Ophthalmology specialty, Series B financing

Beacon Therapeutics, ocular gene therapy, J&J, Series B financing, AGTC-501, rare ophthalmology